

USP7 Inhibits Osteoclastogenesis *via* Dual Effects of Attenuating TRAF6/TAK1 Axis and Stimulating STING Signaling


Ziang Xie^{1,2#,*}, Yizheng Wu^{1,2#}, Yang Shen^{1,2#}, Jiandong Guo³, Putao Yuan^{1,2}, Qingliang Ma^{1,2}, Shiyu Wang^{1,2}, Zhiwei Jie^{1,2}, Hongyi Zhou^{1,2}, Shunwu Fan^{1,2,*}, Shuai Chen^{1,2*}




Supplemental Figure 1. The efficiency of silencing USP7 and overexpression of USP7. The effect of Usp7 sirRNA or overexpression plasmid of USP7 on BMMs was analyzed by qPCR assay. Data are presented as the mean \pm S.D. *, P<0.05. **, P<0.01.




Supplemental Figure 2. The effects of Usp7 siRNA on bone resorption. The effects of NC siRNA or Usp7 siRNA on bone resorption was analyzed by bone slices assay. Scale bar=100 μ m. Data are presented as the mean \pm S.D. **, P<0.01.




Supplemental Figure 3. Cell viability of P5091 on BMMs. (A) The effect of P5091 on BMMs was analyzed by CCK8 assay for treatment with 48h or 96h. Data are presented as the mean \pm S.D. *, P<0.05. ***, P<0.01.




Supplemental Figure 4. The effects of P5091 on osteoclast formation in dose- dependent manner. (A) The effect of different concentrations of P5091 on BMMs was analyzed by TRAP and F-actin assay for treatment 5 days. (B) Quantitative analyses of osteoclast number. (C) The effect of different days of P5091 on BMMs was analyzed by TRAP and F-actin assay for treatment with $2\mu M$. (D) Quantitative analyses of osteoclast number. Data are presented as the mean \pm S.D. *, P<0.05. ***, P<0.01.




Supplemental Figure 5. The effects of P5091 on osteoclast related genes expression. In stimulation with RANKL, the expression of Nfatc1, c-fos, Ctsk and Atp0d2 in RAW264.7 cells were analyzed by qPCR assay in treatment with P5091 (2 μ M) or not. Data are presented as the mean \pm S.D. *, P<0.05. ***, P<0.01.



Supplemental Figure 6. The effects of P5091 on transcription activity of Nfatc1 and NF- κ B. (A) In the presence of M-CSF and RANKL, the BMMs were treated with different concentrations of P5091, the transcription activity of Nfatc1 was tested by dual luciferase reporter genes system. Data are presented as the mean \pm S.D. **, P<0.01. (B) In the presence of M-CSF and RANKL, the BMMs were treated with different concentrations of P5091, the transcription activity of NF- κ B was tested by dual luciferase reporter genes system. Data are presented as the mean \pm S.D. **, P<0.01.



Supplemental Figure 7. The effects of Usp7 overexpress-plasmid on bone resorption. The effects of empty vector or Usp7 plasmid on bone resorption was analyzed by bone slices assay. Scale bar= $100 \, \mu m$. Data are presented as the mean \pm S.D. *, P<0.05.



Supplemental Figure 8. The effects of sh-USP7 on MAPKs and NF-κB signaling pathways in stimulation with M-CSF. In stimulation with M-CSF at different time points,

| the activation alteration of MAPKs and NF- κB signaling pathways by treatment with sh-USP7 | | | | |
|----------------------------------------------------------------------------------------------------|--|--|--|--|
| USP7 | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

Supplementary Table 1. The detailed information for antibodies.

| Regent | Source | Dilution |
|--------------------|----------------------------------------|---------------------|
| Anti-GAPDH | Abcam | WB 1:2500 |
| Anti-β-actin | Abcam | WB 1:2500 |
| Anti-USP7 | Cell Signaling Technology, ProteinTech | WB 1:1000 |
| Anti-NFATc1 | Cell Signaling Technology | WB 1:1000 |
| Anti-c-Fos | Cell Signaling Technology | WB 1:1000 |
| Anti-CTSK | Santacruz, Abcam | WB 1:500, IF 1:200 |
| Anti-TRAP | GeneTex, Abcam | WB 1:1000 |
| Anti-TRAF6 | Santacruz, Abcam | WB 1:1000, IF 1:200 |
| Anti-Ub | Cell Signaling Technology | WB 1:1000 |
| Anti-Ub(K63) | Cell Signaling Technology | WB 1:1000 |
| Anti-Ub(K48) | Cell Signaling Technology | WB 1:1000 |
| Anti-HA | Abcam | WB 1:5000 |
| Anti-Flag | Abcam | WB 1:5000 |
| Anti-Myc | Abcam | WB 1:5000 |
| Anti-ΙκΒα | Cell Signaling Technology | WB 1:1000 |
| Anti-Phospho- TAK1 | Cell Signaling Technology | WB 1:1000 |
| Anti-TAK1 | Cell Signaling Technology | WB 1:1000 |
| Anti-Phosphor-p38 | Cell Signaling Technology | WB 1:1000 |
| Anti-Phospho-JNK | Cell Signaling Technology | WB 1:1000 |
| Anti-Phospho-ERK | Cell Signaling Technology | WB 1:1000 |
| Anti-Total-p38 | Cell Signaling Technology | WB 1:1000 |
| Anti-Total-JNK | Cell Signaling Technology | WB 1:1000 |
| Anti-Total-ERK | Cell Signaling Technology | WB 1:1000 |

SUPPLEMENTARY DATA

Supplementary table 2. Primers for quantitative RT-PCR.

| Genes | Upstream (5'-3') | Downstream (5'-3') |
|--------|---------------------------|--------------------------|
| Gapdh | ACCCAGAAGACTGTGGATGG | CACATTGGGGGTAGGAACAC |
| Ctsk | CTTCCAATACGTGCAGCAGA | TCTTCAGGGCTTTCTCGTTC |
| Acp5 | CTGGAGTGCACGATGCCAGCGAC A | TCCGTGCTCGGCGATGGACCAG A |
| c-Fos | CCAGTCAAGAGCATCAGCAA | AAGTAGTGCAGCCCGGAGTA |
| Nfatc1 | CCGTTGCTTCCAAAAATAACA | TGTGGGATGTGAACTCGGAA |
| Usp7 | GGTGGAATTCCTTGGAGTCTGT | AGTCCTCATTGTCTTGCCTGTT |

Supplementary Table 3. siRNA sequences used in our study.

| Alias | sense (5'-3') | antisense (5'-3') |
|-----------|------------------------|-----------------------|
| si-Usp7#1 | GAGGCAACCUUUCAGUUCAT T | UGAACUGAAAGGUUGCCUCTT |
| si-Usp7#2 | GCGUCCCUUUAGCAUUACAT T | UGUAAUGCUAAAGGGACGCTT |
| si-Usp7#3 | GCCCAAGUUUGAUAAAGAUT T | AUCUUUAUCAAACUUGGGCTT |